MiNK Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for MiNK Therapeutics (INKT).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$42Upside to Avg. PT+313.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$43→$50
May 18, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
Apr 1, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
Aug 15, 2025	HC Wainwright & Co.	Emily Bodnar	Upgrade	Neutral→Buy	$35
Jul 15, 2025	HC Wainwright & Co.	Emily Bodnar	Downgrade	Buy→Neutral	$35
Jul 14, 2025	William Blair	Matt Phipps	Downgrade	Outperform→Market Perform	—
Mar 18, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
Feb 25, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$9→$35
Nov 15, 2024	Baird	Jack Allen	PT Cut	Outperform	$80→$40
Nov 15, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
Oct 9, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
Aug 13, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
May 14, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
Mar 21, 2024	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$100→$90

Analyst Ratings News

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

HC Wainwright & Co. analyst Emily Bodnar upgrades MiNK Therapeutics (NASDAQ:INKT) from Neutral to Buy and maintains the price target from $35 to $35.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains the price target from $35 to $35.

Benzinga Newsdesk

PRO
William Blair Downgrades MiNK Therapeutics to Market Perform

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:INKT) from Outperform to Market Perform.

Benzinga Newsdesk

MiNK Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

MiNK Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

PRO
William Blair Downgrades MiNK Therapeutics to Market Perform

People Also Watch

People Also Watch

MiNK Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

MiNK Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PROHC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PROHC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

PROWilliam Blair Downgrades MiNK Therapeutics to Market Perform

People Also Watch

People Also Watch

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

PRO
William Blair Downgrades MiNK Therapeutics to Market Perform